Carl Ola Landgren (Sylvester Comprehensive Cancer Center): 'I think we have come a long way...we never gave up. I think it’s another example of the fact that if you want to be bold & you want to do something with impact, something that is important, you have to be resilient.'
cancerletter.com/conversation-w…

CHMP recommends approval of Opdivo combination for urothelial carcinoma.
cancerletter.com/drugs-and-targ…

.FDA Oncology's Pazdur: “Multiple myeloma is really a true picture of the success of the accelerated approval program. We have 17 drugs that—almost all of them—were approved on accelerated approval. All of them were approved on non-survival endpoints.'
cancerletter.com/regulatory-new…

Catuvab device removes malignant cells from intraoperative blood salvage procedures.
cancerletter.com/clinical-round…

ODAC’s decision was based on three meta-analyses that examined MRD’s plausibility as an early endpoint by focusing on its correlation with progression-free and overall survival in multiple myeloma.
cancerletter.com/regulatory-new…

Carl Ola Landgren (Sylvester Comprehensive Cancer Center): 'It takes, really, a lot of trust. It takes trust, and you have to have relationships, and you have to also have a clear path to explain to the companies how this is important.'
cancerletter.com/conversation-w…

Ray Blind named associate director for DEI at Vanderbilt-Ingram (Vanderbilt-Ingram Cancer Center).
cancerletter.com/in-brief/20240…

European Commission (European Commission) approves Xtandi for high-risk BCR nmHSPC.
cancerletter.com/drugs-and-targ…

Other factors, such as more multiple myeloma diagnoses, mistrust of the healthcare system, and lack of financial and caregiver support, may also contribute to disparities in treatment utilization, Naseem Esteghamat (UC Davis Comprehensive Cancer Cent) said.
cancerletter.com/health-equity/…

Shanda Blackmon (Shanda Blackmon, MD) named director of Baylor’s Lung Institute.
cancerletter.com/in-brief/20240…

“In the wake of recent cyberattacks targeting our nation’s digital health infrastructure, there is increased urgency to develop straightforward and dependable solutions to protect patients’ data and access to care.” - Director Renee Wegrzyn of ARPA-H.
cancerletter.com/conversation-w…

Health Canada approves Keytruda for gastroesophageal cancer.
cancerletter.com/drugs-and-targ…

The analysis of nearly 30,000 patients diagnosed with multiple myeloma over 26 years in California demonstrated that this disparity has increased over time.
cancerletter.com/health-equity/…

HER2-CAR T-cell therapy induces antitumor activity in high-risk sarcomas in phase I trial.
cancerletter.com/clinical-round…

siRNA halts ccRCC tumor growth in phase I trial (UT Southwestern Medical Center).
cancerletter.com/clinical-round…

In 2009, Carl Ola Landgren (Sylvester Comprehensive Cancer Center) noticed that nearly all of his multiple myeloma patients were responding to the state-of-the-art drugs he was giving them at the NCI clinical center in Building 10 in Bethesda.
cancerletter.com/conversation-w…

FDA approves Anktiva for non-muscle-invasive bladder cancer.
cancerletter.com/drugs-and-targ…

“Over the past five years, there has been a 256% increase in large breaches reported to OCR involving hacking and a 264% increase in ransomware,” HHS officials (HHS OCR) said in a statement March 13.
cancerletter.com/conversation-w…

PRMT5 inhibitor combination overcomes drug resistance in ER+ breast cancer.
cancerletter.com/clinical-round…

Black patients are less likely than patients of other races and ethnicities to receive autologous hematopoietic cell transplants for multiple myeloma, according to a study in the April issue of Clinical Lymphoma, Myeloma, and Leukemia. #HealthEquity
cancerletter.com/health-equity/…